Table 3.
NF-κB staining and ovarian tumor survival outcomes, the VUMC TROC
| Progression-free survival (PFS) | Overall survival (OS) | |||||||
|---|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusted a | Unadjusted | Adjusted a | |||||
| Compartmentalized staining | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
| p52: Non-canonical NF-κB transcription factor | ||||||||
| Cytoplasmic staining | 2.15 (1.55–2.98) | < 0.001 | 1.54 (1.09–2.18) | 0.015 | 1.98 (1.42–2.75) | < 0.001 | 1.53 (1.07–2.18) | 0.019 |
| Nuclear staining | 2.05 (1.46–2.86) | < 0.001 | 1.67 (1.15–2.42) | 0.006 | 1.82 (1.30–2.55) | < 0.001 | 1.49 (1.02–2.17) | 0.041 |
| p65: Canonical NF-κB transcription factor | ||||||||
| Cytoplasmic staining | 1.02 (0.75–1.40) | 0.885 | 1.05 (0.75–1.47) | 0.776 | 1.08 (0.79–1.48) | 0.636 | 1.13 (0.81–1.57) | 0.472 |
| Nuclear staining | 1.40 (1.02–1.92) | 0.037 | 1.20 (0.85–1.69) | 0.300 | 1.37 (1.00–1.89) | 0.052 | 1.31 (0.93–1.84) | 0.124 |
| Total staining | ||||||||
| Independent models | ||||||||
| p52: Cytoplasmic or Nuclear | 1.78 (1.28–2.47) | < 0.001 | 1.53 (1.08–2.19) | 0.018 | 1.73 (1.24–2.41) | 0.001 | 1.61 (1.12–2.33) | 0.011 |
| p65: Cytoplasmic or Nuclear | 1.38 (0.99–1.92) | 0.054 | 1.27 (0.89–1.81) | 0.186 | 1.38 (0.99–1.92) | 0.059 | 1.31 (0.92–1.88) | 0.138 |
| Mutually adjusted models b | ||||||||
| p52: Cytoplasmic or Nuclear | 1.70 (1.21–2.38) | 0.002 | 1.49 (1.04–2.14) | 0.030 | 1.64 (1.16–2.32) | 0.005 | 1.57 (1.08–2.27) | 0.018 |
| p65: Cytoplasmic or Nuclear | 1.24 (0.88–1.73) | 0.217 | 1.18 (0.82–1.71) | 0.348 | 1.22 (0.86–1.72) | 0.260 | 1.23 (0.85–1.77) | 0.265 |
| Among high-grade serous cases c | ||||||||
| Independent models | ||||||||
| p52: Cytoplasmic or Nuclear | 1.79 (1.17–2.75) | 0.007 | 1.68 (1.08–2.62) | 0.020 | 1.65 (1.07–2.56) | 0.024 | 1.61 (1.03–2.53) | 0.038 |
| p65: Cytoplasmic or Nuclear | 0.90 (0.58–1.36) | 0.606 | 1.14 (0.74–1.76) | 0.551 | 1.02 (0.67–1.57) | 0.921 | 1.16 (0.75–1.81) | 0.499 |
| Mutually adjusted models b | ||||||||
| p52: Cytoplasmic or Nuclear | 1.91 (1.23–2.96) | 0.004 | 1.68 (1.07–2.62) | 0.024 | 1.70 (1.09–2.66) | 0.021 | 1.59 (1.01–2.52) | 0.045 |
| p65: Cytoplasmic or Nuclear | 0.76 (0.49–1.18) | 0.223 | 1.03 (0.66–1.61) | 0.899 | 0.89 (0.57–1.39) | 0.612 | 1.09 (0.69–1.69) | 0.719 |
a Adjusted for age at diagnosis (continuous), stage (early, late), histologic subtype (serous, endometrioid and clear cell, mucinous and other), grade (borderline, low, high), and platinum and/or taxane chemotherapy (yes, no or unknown)
b Mutually adjusted models include both p52 and p65 (cytoplasmic or nuclear staining)
c Model does not include adjustment for grade or histologic subtype because only high-grade serous cases (N = 118) were included in this analysis